Ashish Tripathi is the Founder and CEO of Tzar Labs, Singapore, and Chairman of Epigeneres Biotech, India. He leads innovation in molecular diagnostics and precision medicine, focusing on early disease detection. Tzar Labs has developed a novel pan-cancer blood test for early detection across multiple cancer types, including solid and hematological malignancies. The platform targets detection at pre-stage I and early-stage disease with high sensitivity. Ashish is driving the company’s global expansion, with ongoing clinical studies in collaboration with the UK’s NHS and proof-of-concept work in the United States. The company’s research has been published in peer-reviewed journals, including Springer (2021) and Oxford’s Stem Cell (2023), and is supported by granted U.S. patents. Ashish holds an MBA from Melbourne Business School and brings over 20 years of global experience in investment banking, M&A, and corporate strategy, having worked with leading firms including Edelweiss, Ernst & Young, Avendus, Deutsche Bank, and Deloitte.

‍